Eternygen

company

About

Eternygen focuses on research and development of innovative drugs using a network of renowned scientists & contract research organizations.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
€8M
Industries
Biotechnology,Health Care,Health Diagnostics
Founded date
Jun 1, 2012
Number Of Employee
1 - 10
Operating Status
Active

Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity.

Company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€8M
Eternygen has raised a total of €8M in funding over 2 rounds. Their latest funding was raised on Jan 9, 2017 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 9, 2017 Series A €8M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Eternygen is funded by 1 investors. Evotec are the most recent investors.
Investor Name Lead Investor Funding Round
Evotec Series A